In my early years of college, I began working one-on-one with individuals with autism spectrum disorder (ASD), and I knew my future career had to involve this population. I was always fascinated by medicine and psychology, so pursuing a career in clinical psychology gave me the perfect mix of hands-on care and academic research.
The fact that so little was — and continues to be — known about the underlying pathophysiology of ASD intrigues and excites me. I have always appreciated working with both individuals and within the context of their families and environment. It’s just as important to build relationships with individuals with ASD as it is to build relationships with their family members.
Currently, I specialize in diagnostic and behavioral intervention services for people with neurodevelopmental disabilities (NDD), especially ASD. Since joining Cincinnati Children’s Hospital Medical Center, I have provided care primarily within child- and parent-group settings through our intensive outpatient program, Regulating Together. This program was created by Dr. Rebecca Shaffer and focuses on building emotional regulation skills within the NDD population.
My clinical approach in Regulating Together involves teaching caregivers the same intervention strategies as their children. This helps them be better coaches at home. My primary area of research — cognitive flexibility — grew out of the desperate pleas from parents to help reduce their child’s intense behavioral rigidity, which, for many, dictated most of their days.
As a clinical psychology researcher, I use neuroscientific methods to better quantify and understand the underlying pathophysiological processes associated with higher-level skills. Examples include cognitive flexibility, response inhibition and speech production.
Since joining Cincinnati Children’s, I’ve worked with Dr. Craig Erickson and his Fragile X Syndrome (FXS) team to produce an independent line of research. We use electroencephalogram (EEG) to better understand the neural basis of FXS deficits to help speed treatment discovery. I have worked toward establishing an independent line of research implementing cognitive paradigms in individuals with FXS in ongoing biomarker development and drug studies.
Thanks to my collaborative efforts with Dr. Erickson and other physicians within the group, I’ve been involved with numerous clinical drug trials to help differentiate responders from non- responders using EEG and clinical data. This is especially important in FXS, where numerous drug trials have failed despite anecdotal evidence of success in a subset of patients and rescue mouse models of the disorder.
I have also worked with several external collaborators who focus primarily on rodents to develop analogous behavioral paradigms to better advance our knowledge and treatment of NDD. My research efforts have focused on establishing clinical biomarkers of sensorimotor and cognitive deficits in ASD and FXS. I’ve also used neurophysiological techniques to study sensory and cognitive functioning in individuals with FXS.
On a personal note, since moving to Cincinnati in 2017, I have become addicted to spinning classes at Cyclebar. The dark room, loud music and energy is the perfect release after a day of work. It has also given me an empowering and energized community of people outside work and home.
I moved around often when I was younger, so while I struggle to answer, “Where are you from?”, I enjoy sharing all the states I’ve lived in. My father worked for toy companies, and I got to test new toys as a child. Maybe that’s why I enjoy research so much!
Clinical Psychology
Safety, Tolerability, and EEG-Based Target Engagement of STP1 (PDE3,4 Inhibitor and NKCC1 Antagonist) in a Randomized Clinical Trial in a Subgroup of Patients with ASD. Biomedicines. 2024; 12.
Reliability of resting-state electrophysiology in fragile X syndrome. Biomarkers in Neuropsychiatry. 2023; 9.
Results of a phase Ib study of SB-121, an investigational probiotic formulation, a randomized controlled trial in participants with autism spectrum disorder. Scientific Reports. 2023; 13:5192.
A sensitive and reproducible qRT-PCR assay detects physiological relevant trace levels of FMR1 mRNA in individuals with Fragile X syndrome. Scientific Reports. 2023; 13:3808.
Hypersensitivity to Distractors in Fragile X Syndrome from Loss of Modulation of Cortical VIP Interneurons. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2023; 43:8172-8188.
6.30 Regulating Together: Improvements in Youth With ASD and Emotion Dysregulation Enrolled in Virtual Intervention. Journal of the American Academy of Child and Adolescent Psychiatry. 2023; 62:s295.
Behavioral and neuropsychiatric challenges across the lifespan in individuals with Rubinstein-Taybi syndrome. Frontiers in Genetics. 2023; 14:1116919.
Developing improved outcome measures in FXS: Key stakeholder feedback. Research in Developmental Disabilities. 2023; 137:104502.
Regulating Together: Emotion Dysregulation Group Treatment for ASD Youth and Their Caregivers. Journal of Autism and Developmental Disorders. 2023; 53:1942-1962.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey